PCM
SONM icon

Prelude Capital Management’s DNA X Inc SONM Stock Holding History

Prelude Capital Management’s Portfolio SONM Stock Details SONM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Hold
0
– – – 2301
2020
Q2 		– Hold
0
– – – 2232
2019
Q3 		– Sell
-6
Closed -$140K – 2018
2019
Q2 		$140K Buy
+6
New +$152K 0.01% 832

Other funds holding SONM

BRF
B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Nokomis Capital Dallas, Texas $349M AUM 75.66% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
HIM
Herald Investment Management London, United Kingdom $737M AUM 158.15% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Prelude Capital Management's SONM Position: Q3 2020 in Review

Prelude Capital Management held its DNA X Inc (SONM) position steady in Q3 2020 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

Prelude Capital Management first reported a position in SONM in Q2 2019 and has held it in 1 quarter since. The position peaked at $140K in Q2 2019. 34 funds tracked by Wall St. Rank hold SONM as of Q3 2020.

  • Prelude Capital Management held 0 shares of DNA X Inc worth $0 as of Q3 2020.
  • Prelude Capital Management left its DNA X Inc share count unchanged in Q3 2020.
  • DNA X Inc made up ﹤0.01% of Prelude Capital Management's portfolio in Q3 2020, its #2301 holding.
  • Prelude Capital Management first reported a position in DNA X Inc in Q2 2019 and has held it in 1 quarter since.
  • Prelude Capital Management's DNA X Inc position peaked at $140K in Q2 2019.
  • 34 funds tracked by Wall St. Rank held DNA X Inc as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.